Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
Nov 22 OMER Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News
Nov 22 OMER Omeros surges 22% on clarity for BLA resubmission for narsoplimab
Nov 22 BMY AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
Nov 22 JAZZ ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Nov 22 JAZZ Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
Nov 21 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Nov 21 BMY Major companies that are also popular short-selling stocks
Nov 21 OMER Omeros Corporation Provides Update on Progress Toward BLA Resubmission
Nov 21 ALKS Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 PRTC PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 JAZZ Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
Nov 19 INDV Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024
Nov 19 JAZZ Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?
Nov 19 JAZZ Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags